How do I know? Because the senior opthamologist I worked with knows my interest and discussed it with Novartis reps. Novartis was hoping to go with their own Beovue, but after they admitted the problems with inflammation one of their future multibillion dollar treatments evaporated. Novartis was shocked by that. But they've been following Opt302's progress and I bet they're not the only ones now patents have expired.
Ann: Opthea to Host Key Opinion Leader Event on April 3, 2024, page-45
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $376.5M | |||
| Open | High | Low | Value | Volume |
| 34.5¢ | 35.0¢ | 34.0¢ | $402.5K | 1.164M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 506452 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 1059809 | 5 |
View Market Depth
| Last trade - 16.10pm 25/06/2024 (20 minute delay) ? |
| OPT (ASX) Chart |